The acquisition, which was made through Omnicom’s Diversified Agency Services (DAS) division, marks the first time DAS has had a dedicated healthcare unit in China. The move will give Omnicom access to Consultech’s full list of clients, which includes Novartis, Novo Nordisk, Xian-Janssen, Ipsen and China Resources Corp.
David Stark (pictured), president and CEO of DAS Asia-Pacific Healthcare, said the acquisition was partly driven by client demand. “While our agencies do handle healthcare and pharmaceutical clients in China, part of this move was prompted by US-based pharma companies looking for a specialised service in China. This move will allow us to serve those clients, and it will help our agencies in China is terms of business development.”
Consultech, which will be headed by Jiang Song as managing director, boasts 60 staff in Beijing, where it is headquartered, and Shanghai.
